Skip to main content

Table 3 Acute adverse events

From: Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial

AEs

N = 108 (%)

Grade 1–2

Grade 3

Grade 4

Hematological

 Leukopenia

32 (29.6%)

26 (24.1%)

35 (32.4%)

 Neutropenia

25 (23.1%)

23 (21.3%)

40 (37.0%)

 Anemia

65 (60.2%)

10 (9.3%)

1 (0.9%)

 Thrombocytopenia

69 (63.9%)

18 (16.7%)

5 (4.6%)

Nonhematological

 Acid reflux/vomiting

58 (53.7%)

0

3 (2.8%)

 Hiccup

30 (27.8%)

0

0

 Fever

12 (11.1%)

0

0

 Hair loss

58 (53.7%)

0

0

 Muscular soreness

23 (21.3%)

0

0

 Neurotoxicity

3 (2.8%)

0

0

Radiation-induced

 Dermatitis

45 (41.7%)

0

0

 Esophagitis

84 (77.8%)

0

0

 Pneumonitis

53 (49.1%)

1 (0.9%)

0